FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression

Estimate the maximum tolerated dose and/or recommended phase II dose by detecting the Dose
Limiting Toxicity and efficacy of FGF401 as single agent and in combination with PDR001 in
patients with hepatocellular carcinoma and as single agent in patients with other solid
malignancies based on RECIST 1.1.

Inclusion Criteria:

1. ECOG Performance Status ≤ 1

2. Presence of at least one measurable lesion according to RECIST v1.1. c-i) FGF401
single agent-Phase I and Phase II, Group 3: Patients with HCC or advanced solid
tumors, who have progressed despite standard therapy or are intolerant of standard
therapy, or for whom no standard therapy exists. c-ii) FGF401 single agent-Phase II,
Groups 1 and 2: HCC patients previously treated with sorafenib for advanced HCC with
documented disease progression during or after discontinuation of sorafenib treatment,
or intolerance to sorafenib treatment c-iii) FGF401 in combination with
PDR001:Advanced HCC patients who have received up to 2 previous lines of systemic
treatment and one treatment must have included sorafenib with documented disease
progression during or after discontinuation of sorafenib treatment, or intolerance to
sorafenib treatment

Exclusion Criteria:

1. Previous treatment with a selective FGF19-FGFR4 targeted therapy and/or pan-FGFR
inhibitor.

2. Symptomatic CNS metastases which are neurologically unstable or requiring increasing
doses of steroids to control their CNS disease.

3. Patient having out of range laboratory values defined as:

- Hematology Hemoglobin ≤ 9 g/dL (SI Units: 90 g/L) Platelet count < 75000/mm3
Absolute neutrophil count (ANC) < 1500/mm3

- Chemistry Total bilirubin ≥ 2 mg/dL AST and/or ALT > 3 x ULN Serum creatinine >
1.5 x ULN and/or creatinine clearance ≤ 45 mL/min

- Coagulation: PT > 4 seconds more than ULN or INR > 1.7

4. Pregnant or nursing (lactating) women.

Other protocol-defined Inclusion/Exclusion criteria may apply.